

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Hack Andrew A. F.</u>			2. Issuer Name and Ticker or Trading Symbol <u>DYNAVAX TECHNOLOGIES CORP [DVAX]</u>			5. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director 10% Owner Officer (give title below) Other (specify below)		
(Last)	(First)	(Middle)	3. Date of Earliest Transaction (Month/Day/Year) <u>03/11/2020</u>					
<u>C/O BAIN CAPITAL LIFE SCIENCES INVESTORS</u> <u>200 CLARENDON STREET</u>			4. If Amendment, Date of Original Filed (Month/Day/Year)			6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person Form filed by More than One Reporting Person		
(Street)								
<u>BOSTON</u>	<u>MA</u>	<u>02116</u>						
(City)	(State)	(Zip)						

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
						Date Exercisable	Expiration Date	Title	Amount or Number of Shares				
<u>Right to Exchange</u>	<u>(1)(2)</u>	<u>03/11/2020</u>		<u>A</u>	<u>1⁽¹⁾⁽²⁾</u>	<u>03/11/2020</u>	<u>02/12/2022</u>	<u>Preferred Warrants(Right to Buy)</u>	<u>2,916.25⁽¹⁾⁽²⁾</u>	<u>\$0.00</u>	<u>1⁽¹⁾⁽²⁾</u>	<u>I</u>	<u>See Footnotes⁽¹⁾⁽²⁾⁽³⁾</u>

Explanation of Responses:

- On March 11, 2020, each of Bain Capital Life Sciences Fund, L.P. ("BCLSF") and BCIP Life Sciences Associates, LP ("BCIPLS") and, together with BCLSF, the "Bain Life Sciences Entities") entered into a letter agreement with the Issuer that provides the Bain Life Sciences Entities with the right, on one occasion, to exchange all or any portion of the warrants to purchase an aggregate of 2,916,250 shares of the Issuer's common stock (each, a "Warrant") owned by the Bain Life Sciences Entities for one or more warrants (each, a "Preferred Warrant") to purchase shares of the Issuer's non-voting Series C Convertible Preferred Stock (the "Series C Preferred Stock"). Each share of Series C Preferred Stock will be convertible, at the option of the holder, into 1,000 shares of the Issuer's common stock.
- (Continued from footnote 1) Each Preferred Warrant issued in exchange for a Warrant will have an exercise price of \$4,500 per share of Series C Preferred Stock and will be exercisable for a number of shares of Series C Preferred Stock equal to (x) the number of shares of Common Stock for which the Warrant then remains exercisable, divided by (y) 1,000. The Warrants, the Series C Preferred Stock and the Series B Convertible Preferred Stock held by the Bain Life Sciences Entities each include provisions prohibiting exercise or conversion into the Issuer's common stock to the extent such exercise or conversion would result in beneficial ownership of the Issuer's common stock in excess of 9.99%.
- Bain Capital Life Sciences Investors, LLC ("BCLSI") is the ultimate general partner of BCLSF, and governs the investment strategy and decision-making process with respect to investments held by BCIPLS. Dr. Hack is a Managing Director of BCLSI. By virtue of the relationships described in this footnote, Dr. Hack may be deemed to share voting and dispositive power with respect to the securities held by the Bain Life Sciences Entities. Dr. Hack disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

/s/ Andrew A.F. Hack

03/12/2020

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.